Paclitaxel :Sources, Chemistry, Anticancer Actions, and Current Biotechnology
Paclitaxel :Sources, Chemistry, Anticancer Actions, and Current Biotechnology
paperback
Published:
11 October, 2021
Description
More Details
| Type | Book |
|---|---|
| ISBN13 | 9780323909518 |
| ISBN10 | 0323909515 |
| Number Of Pages | 354 |
| Item Weight | 450 g |
| Publisher / Reseller | Elsevier Science & Technology |
| Format | paperback |
Author's Bio
Mallappa Kumara Swamy, PhD, completed his Postdoctoral Research at the Department of Crop Science, Faculty of Agriculture, Universiti Putra Malaysia (UPM), from 2014-2018. He has more than 16 years of teaching and research experience in the fields of plant biotechnology, secondary metabolites production, phytochemistry and bioactive studies. Dr. Swamy has published more than 100 research publications in peer- reviewed journals, 25 book chapters and has edited 10 books with reputed international publishers. His research focuses on the area of natural products, plant cell, tissue culture technology for bioactive compounds production and evaluation of their bioactivities, and nanobiotechnology for medical applications. T. Pullaiah earned his PhD from Andhra University and then pursued a postdoctoral fellowship at Moscow State University (1976–1978). He is a former Professor of Botany at Sri Krishnadevaraya University, where he taught for more than 35 years. He served as president of the Indian Botanical Society in 2014 and of the Indian Association for Angiosperm Taxonomy in 2013. His honors include the Panchanan Maheshwari Gold Medal, the Prof. P. C. Trivedi Medal, the Dr. G. Panigrahi Memorial Lecture Award of the Indian Botanical Society, and the Prof. Y. D. Tyagi Gold Medal of IAAT. A prolific author and editor, Prof. Pullaiah has mentored students throughout his career and, for several years, has also been a member of the IUCN Species Survival Commission, a global network of over 10,000 volunteer experts dedicated to conserving biodiversity and preventing species extinction through science-based action and collaboration. Zhe-Sheng Chen, PhD, opened the St. John’s University’s first cancer pharmacology laboratory. His research interest is multidrug resistance and its reversal, novel anti-cancer drug development. Chen has over 170 papers published, co-edited Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy book (Elsevier), and holds 5 patents.